Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Mallinckrodt
AstraZeneca
Boehringer Ingelheim
Medtronic

Last Updated: September 25, 2022

QBRELIS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Qbrelis patents expire, and what generic alternatives are available?

Qbrelis is a drug marketed by Azurity and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has ten patent family members in eight countries.

The generic ingredient in QBRELIS is lisinopril. There are twenty-one drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the lisinopril profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Qbrelis

A generic version of QBRELIS was approved as lisinopril by ASCENT PHARMS INC on July 1st, 2002.

  Try it Free

Drug patent expirations by year for QBRELIS
Drug Prices for QBRELIS

See drug prices for QBRELIS

Recent Clinical Trials for QBRELIS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
St. Jude Children's Research HospitalPhase 2
National Cancer Institute (NCI)Phase 2
Mayo ClinicPhase 2

See all QBRELIS clinical trials

Pharmacology for QBRELIS
Paragraph IV (Patent) Challenges for QBRELIS
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
QBRELIS Oral Solution lisinopril 1 mg/mL 208401 1 2019-10-24

US Patents and Regulatory Information for QBRELIS

QBRELIS is protected by twenty-six US patents.

Patents protecting QBRELIS

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE MYOCARDIAL INFARCTION

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF MYOCARDIAL INFARCTION

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATMENT OF HEART FAILURE

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HEART FAILURE

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HYPERTENSION

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING HYPERTENSION

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF MYOCARDIAL INFARCTION

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING HYPERTENSION

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HEART FAILURE

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATMENT OF HEART FAILURE

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HYPERTENSION

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE MYOCARDIAL INFARCTION

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing


Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HYPERTENSION

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING HYPERTENSION

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HEART FAILURE

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF MYOCARDIAL INFARCTION

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE MYOCARDIAL INFARCTION

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATMENT OF HEART FAILURE

Lisinopril formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Azurity QBRELIS lisinopril SOLUTION;ORAL 208401-001 Jul 29, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Azurity QBRELIS lisinopril SOLUTION;ORAL 208401-001 Jul 29, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Azurity QBRELIS lisinopril SOLUTION;ORAL 208401-001 Jul 29, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Azurity QBRELIS lisinopril SOLUTION;ORAL 208401-001 Jul 29, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Azurity QBRELIS lisinopril SOLUTION;ORAL 208401-001 Jul 29, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Azurity QBRELIS lisinopril SOLUTION;ORAL 208401-001 Jul 29, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for QBRELIS

See the table below for patents covering QBRELIS around the world.

Country Patent Number Title Estimated Expiration
Spain 2886869 See Plans and Pricing
China 112972370 赖诺普利制剂 (LISINOPRIL FORMULATIONS) See Plans and Pricing
South Korea 20180069907 리시노프릴 제제 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2017075368 See Plans and Pricing
China 108472252 赖诺普利制剂 (LISINOPRIL FORMULATIONS) See Plans and Pricing
Hong Kong 1258803 賴諾普利製劑 (LISINOPRIL FORMULATIONS) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Express Scripts
Colorcon
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.